Shares Bazaar

Glenmark Pharmaceuticals Ltd.

NSE   0.00  
OPEN PRICE(₹)
0.00
HIGH PRICE(₹)
0.00
LOW PRICE(₹)
0.00
CLOSE PRICE(₹)
0.00
VOLUME
0.00
52 WK LOW (₹)
161.65 (13-03-2020)
52 WK HIGH (₹)
573.05 (22-06-2020)
BSE   591.8  
OPEN PRICE₹)
570
HIGH PRICE(₹)
602.4
LOW PRICE (₹)
565.5
CLOSE PRICE(₹)
591.8
VOLUME
494235
VALUE
292564000
BID QTY
0
OFFER QTY
0

Stock Summary

Trade Value (₹ in Lacs) : 282.17 MCap (₹ in Mn) : 135638.23 Dividend Yield(%) : 0.52 Price/Earning (TTM) : 8.69
TTM EPS (₹) : 0 Price/Sales (TTM) : 0 P/E Ratio : 0.01 Price/Book (MRQ) : 0.97
Book Value(₹) : 0 Face Value(₹) : 0 Latest Reserve (₹ in Mn): 139963.5 EPSc : 48
PE : 10.01 TTMNP : 15600.65 TTMTAX : 2605.17 TTMINTEREST : 2434.97
TTMDEPRECIATION : 1456.54 TTMNetSales : 69712.81 EV_Sales : 2.45 EV (in Mn) : 170493.27
TTMEBITDA : 21631.89 EV_EBITDA : 7.88 TTMCashProfit : 17057.19 TTMCEPS : 60.45
Price_CEPS : 7.95 TTMNPAEX : 15600.65

Peer Group Compare

Comp. Name Price M.Cap Div Yld % P/E Ratio Price/Earning (TTM) TTM EPS (₹)
Sun Pharmaceutical Industries Ltd. (BSE)

679.5 ( 0.04%)

135418.47 0.71 0 47 12.01
Divis Laboratories Ltd. (BSE)

4029.5 ( -0.81%)

91003.96 0.47 0.06 51.76 66.23
Dr. Reddys Laboratories Ltd. (BSE)

5173.55 ( 0.15%)

81092.78 0.51 0.04 33.02 147.67
Cipla Ltd. (BSE)

882.95 ( -0.1%)

67867.68 0.48 0.01 30.26 27.81
Aurobindo Pharma Ltd. (BSE)

1012.75 ( 0.42%)

55333.11 0.32 0.01 20.8 45.4

Management Info

Chairman : Glenn Saldanha
Managing Director : Glenn Saldanha
Company Secretory : Harish Kuber
Incorporation Year : 1977

Registered Office

Address : B/2 Mahalaxmi Chambers
22 Bhulabhai Desai Road

City-Pincode : Mumbai-400026
Phone :
Website : www.glenmarkpharma.com
Email : webmaster@glenmarkpharma.com

Registrars Details

Registrars Details : K FIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.)
Address : Karvy Selenium Tower B, Plot 31-32Gachibowli,Financial District, NanakramgudaHyderabad – 500032Tel. No. 040 67161500Fax. No. 040 23001153E-mail: einward.ris@karvy.comWebsite: www.karvy.comToll Free No. of exclusive Call Centre:1-800-345001
Listing : BSE, NSE, MCX

loading..

Balance Sheet

(₹ in Million)
Particulars Mar-2020 Mar-2019 Mar-2018 Mar-2017 Mar-2016
SOURCES OF FUNDS:
Share Capital 0.28 0.28 0.28 0.28 0.28
  Equity - Authorised 2.37 2.37 2.37 2.37 2.37
  Equity - Issued 0.28 0.28 0.28 0.28 0.28
 Equity Paid Up 0.28 0.28 0.28 0.28 0.28
  Equity Shares Forfeited 0.00 0.00 0.00 0.00 0.00
  Adjustments to Equity 0.00 0.00 0.00 0.00 0.00
  Preference Capital Paid Up 0.00 0.00 0 0 0.00
  Face Value 0 0 0 0 0
Share Warrants & Outstandings 0.00 0.00 0.00 0.00 0.00
Total Reserves 60.29 55.66 51.25 44.63 36
  Securities Premium 16.85 16.85 16.85 16.85 16.85
  Capital Reserves 0 0 0 0 0
  Profit & Loss Account Balances 63.3 56.15 47.79 40.4 30.02
  General Reserves 1.46 1.46 1.46 1.46 1.46
Reserve excluding Revaluation Reserve 60.29 55.66 51.25 44.63 36
Revaluation Reserves 0.00 0.00 0 0 0.00
Deposits 0.00 0.00 0.00 0.00 0.00
  Demand Deposits 0.00 0.00 0.00 0.00 0.00
  Savings Deposit 0.00 0.00 0.00 0.00 0.00
  Term Deposits / Fixed Deposits 0.00 0.00 0.00 0.00 0.00
  Current Deposits 0.00 0.00 0.00 0.00 0.00
  Recurring Deposits 0.00 0.00 0.00 0.00 0.00
  Other Deposits 0.00 0.00 0.00 0.00 0.00
Borrowings 0.00 0.00 0.00 0.00 0.00
  Borrowings From Reserve Bank of India 0.00 0.00 0.00 0.00 0.00
  Borrowings From Other Banks 0.00 0.00 0.00 0.00 0.00
  Borrowings From GOI 0.00 0.00 0.00 0.00 0.00
  Borrowings From Other Financial Institutions 0.00 0.00 0.00 0.00 0.00
  Borrowings in the form of Bonds / Debentures 0.00 0.00 0.00 0.00 0.00
  Borrowings in Other Form 0.00 0.00 0.00 0.00 0.00
Other Liabilities & Provisions 0.00 0.00 0.00 0.00 0.00
  Bills Payable 0.00 0.00 0.00 0.00 0.00
  Inter-office adjustment Liabilities 0.00 0.00 0.00 0.00 0.00
  Interest Accrued 0.00 0.00 0.00 0.00 0.00
  Proposed Dividend 0.00 0.00 0.00 0.00 0.00
  Corporate dividend tax payable 0.00 0.00 0.00 0.00 0.00
  Other Liabilities & Provisions 0.00 0.00 0.00 0.00 0.00
Total Liabilities 105.42 92.68 93.07 90.61 61.94
APPLICATION OF FUNDS :
Cash and balance with Reserve Bank of India 0.00 0.00 0.00 0.00 0.00
  Cash with RBI 0.00 0.00 0.00 0.00 0.00
  Cash in hand & others 0.00 0.00 0.00 0.00 0.00
Balances with banks and money at call 0.00 0.00 0.00 0.00 0.00
Investments 1.75 1.4 1.35 1.15 0.87
Investments in India 0.00 0.00 0.00 0.00 0.00
  GOI/State Govt. Securities 0.00 0.00 0.00 0.00 0.00
  Equity Shares - Corporate 0.00 0.00 0.00 0.00 0.00
  Debentures & Bonds 0.00 0.00 0.00 0.00 0.00
  Subsidiaries and/or joint ventures/Associates 0.00 0.00 0.00 0.00 0.00
  Units - MF/ Insurance/CP/PTC 0.00 0.00 0.00 0.00 0.00
Investments outside India 0.00 0.00 0.00 0.00 0.00
  Government securitiesC 0.00 0.00 0.00 0.00 0.00
  Subsidiaries and/or joint ventures abroad 0.00 0.00 0.00 0.00 0.00
  Other investments outside India 0.00 0.00 0.00 0.00 0.00
  Less: Prov for Diminution in Value of Invest. 0.00 0.00 0.00 0.00 0.00
Advances 0.00 0.00 0.00 0.00 0.00
  Bills Purchased & Discounted 0.00 0.00 0.00 0.00 0.00
  Cash Credit, Over Draft & Loans repayable 0.00 0.00 0.00 0.00 0.00
  Term Loans 0.00 0.00 0.00 0.00 0.00
  Finance lease and hire purchase receivable 0.00 0.00 0.00 0.00 0.00
Gross block 82.7 65.27 53.68 47.7 43.01
  Premises 16.09 10.38 8.96 8.11 7.25
  Assets Given on Lease 0.00 0.00 0.00 0.00 0.00
  Other Fixed Assets 0.00 0.00 0.00 0.00 0.00
Less: Accumulated Depreciation 32.41 28.57 23.38 20.15 17.07
Net Block 50.29 36.7 30.3 27.55 25.94
Less: Impairment of Assets 0.00 0.00 0.00 0.00 0.00
Lease Adjustment 0.00 0.00 0.00 0.00 0.00
Capital Work in Progress 12.22 13.99 11.22 7.08 5.43
Other Assets 0.00 0.00 0.00 0.00 0.00
  Inter-office adjustment Assets 0.00 0.00 0.00 0.00 0.00
  Interest Accrued Assets 0.00 0.00 0.00 0.00 0.00
  Tax paid in advance/TDS 0.00 0.00 0.00 0.00 0.00
  Stationery and stamps 0.00 0.00 0.00 0.00 0.00
  Non-banking assets acquired 0.00 0.00 0.00 0.00 0.00
  Deferred tax asset 0.00 0.00 0.00 0.00 0.00
  Miscellaneous Expenditure not written off 0.00 0.00 0.00 0.00 0.00
Total Assets 105.42 92.68 93.07 90.61 61.94
Contingent Liabilities 2.71 0.74 0.47 0.37 0.37
  Claims not acknowledged as debts 0.47 0.56 0.33 0.28 0.27
  Outstanding forward exchange contracts 0.00 0.00 0.00 0.00 0.00
  Guarantees given in India 0.00 0.00 0.00 0.00 0.00
  Guarantees given Outside India 0.00 0.00 0.00 0.00 0.00
  Acceptances, endorsements & other obligations 0.00 0.00 0.00 0.00 0.00
Bills for collection 0.00 0.00 0.00 0.00 0.00
Book Value 0.21 0.2 0.18 0.16 0.13
Adjusted Book Value 0.21 0.2 0.18 0.16 0.13
(₹ in Million)
Particulars Mar-2020 Mar-2019 Mar-2018 Mar-2017 Mar-2016
SOURCES OF FUNDS:
Share Capital 0.28 0.28 0.28 0.28 0.28
  Equity - Authorised 2.37 2.37 2.37 2.37 2.37
  Equity - Issued 0.28 0.28 0.28 0.28 0.28
 Equity Paid Up 0.28 0.28 0.28 0.28 0.28
  Equity Shares Forfeited 0.00 0.00 0.00 0.00 0.00
  Adjustments to Equity 0.00 0.00 0.00 0.00 0.00
  Preference Capital Paid Up 0.00 0.00 0.00 0.00 0.00
  Face Value 0 0 0 0 0
Share Warrants & Outstandings 0.00 0.00 0.00 0.00 0.00
Total Reserves 131.84 119.03 103.53 94.07 73.36
  Securities Premium 16.85 16.85 16.85 16.85 16.85
  Capital Reserves 0 0 0 0 0
  Profit & Loss Account Balances 113.4 100.59 85.09 75.63 54.93
  General Reserves 1.38 1.38 1.38 1.38 1.38
Reserve excluding Revaluation Reserve 131.84 119.03 103.53 94.07 73.36
Revaluation Reserves 0.00 0.00 0.00 0.00 0.00
Deposits 0.00 0.00 0.00 0.00 0.00
  Demand Deposits 0.00 0.00 0.00 0.00 0.00
  Savings Deposit 0.00 0.00 0.00 0.00 0.00
  Term Deposits / Fixed Deposits 0.00 0.00 0.00 0.00 0.00
  Current Deposits 0.00 0.00 0.00 0.00 0.00
  Recurring Deposits 0.00 0.00 0.00 0.00 0.00
  Other Deposits 0.00 0.00 0.00 0.00 0.00
Borrowings 0.00 0.00 0.00 0.00 0.00
  Borrowings From Reserve Bank of India 0.00 0.00 0.00 0.00 0.00
  Borrowings From Other Banks 0.00 0.00 0.00 0.00 0.00
  Borrowings From GOI 0.00 0.00 0.00 0.00 0.00
  Borrowings From Other Financial Institutions 0.00 0.00 0.00 0.00 0.00
  Borrowings in the form of Bonds / Debentures 0.00 0.00 0.00 0.00 0.00
  Borrowings in Other Form 0.00 0.00 0.00 0.00 0.00
Other Liabilities & Provisions 0.00 0.00 0.00 0.00 0.00
  Bills Payable 0.00 0.00 0.00 0.00 0.00
  Inter-office adjustment Liabilities 0.00 0.00 0.00 0.00 0.00
  Interest Accrued 0.00 0.00 0.00 0.00 0.00
  Proposed Dividend 0.00 0.00 0.00 0.00 0.00
  Corporate dividend tax payable 0.00 0.00 0.00 0.00 0.00
  Other Liabilities & Provisions 0 0 0 9.91 6.76
Total Liabilities 165.63 148.62 130.8 130.2 80.46
APPLICATION OF FUNDS :
Cash and balance with Reserve Bank of India 0.00 0.00 0.00 0.00 0.00
  Cash with RBI 0.00 0.00 0.00 0.00 0.00
  Cash in hand & others 0.00 0.00 0.00 0.00 0.00
Balances with banks and money at call 0.00 0.00 0.00 0.00 0.00
Investments 119.11 95.9 66.1 65.8 40.46
Investments in India 0.00 0.00 0.00 0.00 0.00
  GOI/State Govt. Securities 0.00 0.00 0.00 0.00 0.00
  Equity Shares - Corporate 0.00 0.00 0.00 0.00 0.00
  Debentures & Bonds 0.00 0.00 0.00 0.00 0.00
  Subsidiaries and/or joint ventures/Associates 0.00 0.00 0.00 0.00 0.00
  Units - MF/ Insurance/CP/PTC 0.00 0.00 0.00 0.00 0.00
Investments outside India 0.00 0.00 0.00 0.00 0.00
  Government securitiesC 0.00 0.00 0.00 0.00 0.00
  Subsidiaries and/or joint ventures abroad 0.00 0.00 0.00 0.00 0.00
  Other investments outside India 0.00 0.00 0.00 0.00 0.00
  Less: Prov for Diminution in Value of Invest. 0.00 0.00 0.00 0.00 0.00
Advances 0.00 0.00 0.00 0.00 0.00
  Bills Purchased & Discounted 0.00 0.00 0.00 0.00 0.00
  Cash Credit, Over Draft & Loans repayable 0.00 0.00 0.00 0.00 0.00
  Term Loans 0.00 0.00 0.00 0.00 0.00
  Finance lease and hire purchase receivable 0.00 0.00 0.00 0.00 0.00
Gross block 25.95 22.6 25.82 23.69 21.07
  Premises 6.89 5.52 6.15 5.51 4.87
  Assets Given on Lease 0.00 0.00 0.00 0.00 0.00
  Other Fixed Assets 0.00 0.00 0.00 0.00 0.00
Less: Accumulated Depreciation 9.83 8.47 8.83 7.72 6.69
Net Block 16.12 14.13 16.99 15.96 14.38
Less: Impairment of Assets 0 0 0 0 0
Lease Adjustment 0.00 0.00 0.00 0.00 0.00
Capital Work in Progress 2 2.86 4.2 2.71 2.76
Other Assets 0.00 0.00 0.00 0.00 0.00
  Inter-office adjustment Assets 0.00 0.00 0.00 0.00 0.00
  Interest Accrued Assets 0.00 0.00 0.00 0.00 0.00
  Tax paid in advance/TDS 0.00 0.00 0.00 0.00 0.00
  Stationery and stamps 0.00 0.00 0.00 0.00 0.00
  Non-banking assets acquired 0.00 0.00 0.00 0.00 0.00
  Deferred tax asset 0.00 0.00 0.00 0.00 0.00
  Miscellaneous Expenditure not written off 0.00 0.00 0.00 0.00 0.00
Total Assets 165.63 148.62 130.8 130.2 80.46
Contingent Liabilities 44.31 36.81 45.5 37.21 45.94
  Claims not acknowledged as debts 0.44 0.38 0.29 0.26 0.27
  Outstanding forward exchange contracts 0.00 0.00 0.00 0.00 0.00
  Guarantees given in India 0.00 0.00 0.00 0.00 0.00
  Guarantees given Outside India 0.00 0.00 0.00 0.00 0.00
  Acceptances, endorsements & other obligations 0.00 0.00 0.00 0.00 0.00
Bills for collection 0.00 0.00 0.00 0.00 0.00
Book Value 0.47 0.42 0.37 0.33 0.26
Adjusted Book Value 0.47 0.42 0.37 0.33 0.26

Quarterly Results

Particulars Sep-2020 Jun-2020 Mar-2020 Feb-2019
Date End Audited Audited Audited Audited
Interest Earned 29524.79 23447.87 27674.89 27355.61
Income On Investments 0.00 0.00 0.00 0.00
Interest On Balances With Rbi Other Inter Bank Funds 0.00 0.00 0.00 0.00
Interest / Discount On Advances / Bills 0 0 0 0
Others 0 0 0 0
Other Income -318.81 585.14 441.45 329.63
Total Income 29205.98 24033.01 28116.34 27685.24
Interest Expended 806.32 937.4 984.74 960.58
Operating Expenses 0 0 0 0
Total Expenditure 23996.66 18667.19 23018.02 22954.86
Operating Profit Before Provisions and Contingencies 5209.32 5365.82 5098.32 4730.38
Exceptional Items 31.4 279.9 328.76 0
Provisions and contingencies 0 0 0 0
Profit Before Tax 3393.75 3576.1 3179.59 2709.81
Tax 1053.82 1035.68 976.51 801.42
Profit After Tax 2339.93 2540.42 2203.08 1908.39
+/- Extraordinary Items 0 0 0 0
+/- Prior period items 0 0 0 0
Net Profit 2339.93 2540.42 2203.08 1908.39
Minority Interest 0 0 0 -0.95
Shares of Associates 0 0 0 0
Other related items 0 0 0 0
Misc. Expenses Written off 0.00 0.00 0.00 0.00
Consolidated Net Profit 2339.93 2540.42 2203.08 1908.39
Equity Capital 2339.93 2540.42 2203.08 1907.44
Face Value (IN RS) 1 1 1 1
Reserves 0 0 0 0
% of Shares held by Govt 0 0 0 0
Capital Adequacy Ratio 0.00 0.00 0.00 0.00
Gross / Net NPAs 0.00 0.00 0.00 0.00
Amount of Gross NPAs 0.00 0.00 0.00 0.00
Amount of Net NPAs 0 0 0 0
% of Gross / Net NPAs NA NA NA NA
% of Net NPAs 0 0 0 0
% of Gross NPAs 0 0 0 0
Return on Assets 0 0 0 0
No of Public Share Holdings NA NA NA NA
% of Public Share Holdings NA NA NA NA
Basic Eps After Extraordinary Items 8.29 9 7.81 6.76
Basic Eps Before Extraordinary Items 8.29 9 7.81 6.76
PBIDTM% 17.64 22.88 18.42 17.29
PBDTM% 15.02 20.08 16.05 13.78
PBTM% 11.49 15.25 11.49 9.91
PATM% 7.93 10.83 7.96 6.98
Particulars Sep-2020
Date End Audited
Interest Earned 20621.7
Income On Investments 0
Interest On Balances With Rbi Other Inter Bank Funds 0
Interest / Discount On Advances / Bills 0
Others 0.00
Other Income 634
Total Income 21255.7
Interest Expended 604.1
Operating Expenses 0.00
Total Expenditure 15668.1
Operating Profit Before Provisions and Contingencies 5587.6
Exceptional Items 0
Provisions and contingencies 0.00
Profit Before Tax 4615.5
Tax 586.8
Profit After Tax 4028.8
+/- Extraordinary Items 0.00
+/- Prior period items 0.00
Net Profit 4028.8
Minority Interest 0.00
Shares of Associates 0.00
Other related items 0.00
Misc. Expenses Written off 0.00
Consolidated Net Profit 4028.8
Equity Capital 4028.8
Face Value (IN RS) 1
Reserves 0
% of Shares held by Govt 0.00
Capital Adequacy Ratio 0.00
Gross / Net NPAs 0.00
Amount of Gross NPAs 0.00
Amount of Net NPAs 0.00
% of Gross / Net NPAs NA
% of Net NPAs 0.00
% of Gross NPAs 0.00
Return on Assets 0.00
No of Public Share Holdings NA
% of Public Share Holdings NA
Basic Eps After Extraordinary Items 14.28
Basic Eps Before Extraordinary Items 14.28
PBIDTM% 27.1
PBDTM% 24.17
PBTM% 22.38
PATM% 19.54

Profit-Loss

-
Particulars Mar-2020 Mar-2019 Mar-2018 Mar-2017 Mar-2016
I. INCOME
Interest Earned 0 0 0 0 0
     Interest / Discount on advances / Bills 0 0 0 0 0
     Interest on balances with RBI and other Inter-bank funds 0 0 0 0 0
     Income on investments 0 0 0 0 0
     Others 0 0 0 0 0
Other Income
     Commission,exchange and brokerage 0 0 0 0 0
     Profit / (loss)on sale of investments(net) 0 0 0 0 0
     Profit on sale of Fixed Assets 0 0.01 0 0.02 0
     Foreign Exchange Gains 1.38 1.77 0.69 0 0
     Income earned from subsidiaries/joint venture 0 0 0 0 0
     Rent / Lease Income
     Provisions Written Back 0 0 0 0 0
     Miscellaneous income 0 -2081.37 0 0 200
Total Income 108.01 100.74 91.66 91.17 75.82
II. EXPENDITURE
Interest Expended 3.77 3.35 2.86 2.37 1.79
     Intereston Deposits 0 0 0 0 0
     Interest on RBI / inter-bank borrowings 0 0 0 0 0
     Other Interest 0.42 0.24 0.74 0.13 0.33
Operating Expenses 0 0 0 0 0
     Payments to and provisions for employees 22.55 20.56 18.72 16.41 13.78
     Rent,Taxes and lighting 0.58 1.17 0.94 0.84 0.92
     Depreciation on Banks property 4.17 3.26 3.02 2.64 2.34
     Depreciation on leased assets
     Auditor's fees and expenses 0.1 0.09 0.07 0.07 0.05
     Law charges 3.18 2.34 1.74 1.83 1.57
     Communication Expenses 0.09 0.1 0.12 0.12 0.12
     Repairs and Maintenance 0 0 0 0 0
     Insurance 0.28 0.22 0.15 0.2 0.19
     Other expenses -30.95 -27.74 -24.75 -22.11 -18.98
Provisions and Contingencies
     Provision for investments
     Provision for advances
     Others Provisions
Profit Before Tax 104.23 97.39 88.8 88.79 74.03
Taxes
     Current Income Tax 3.96 4.77 3.26 6.19 5.11
     Deferred Tax -0.76 -1.01 -0.1 -2.36 -2.11
     Other taxes 0 0 0 0 0
Profit After Tax 7.76 9.25 8.04 11.09 7.43
Extra items
Minority Interest -0 -0 -0 0 0
Share of Associate
Other Consolidated Items
Consolidated Net Profit 7.76 9.25 8.04 11.09 7.43
Adjustments to PAT
IV. APPROPRIATIONS
     Transfer to Statutory Reserve
     Appropriation to General Reserve
     Appropriation to Revenue Reserve
     Appropriation to Other Reserves 0.61 0.89 0.64 0.71 -0.3
     Equity Dividend 0.56
     Corporate dividend tax 0.11
     Other appropriations 63.3 56.15 47.79 40.4 30.02
Equity Dividend % 250.00 200.00 200.00 200.00 200.00
Earnings Per Share 27.5000 32.7810 28.4856 39.2954 26.3410
Adjusted EPS 27.5000 32.7810 28.4856 39.2954 26.3410
-
Particulars Mar-2020 Mar-2019 Mar-2018 Mar-2017 Mar-2016
I. INCOME
Interest Earned 0 0 0 0 0
     Interest / Discount on advances / Bills 0 0 0 0 0
     Interest on balances with RBI and other Inter-bank funds 0 0 0 0 0
     Income on investments 0 0 0 0 0
     Others 0 0 0 0 0
Other Income
     Commission,exchange and brokerage 0 0 0 0 0
     Profit / (loss)on sale of investments(net) 0 0 0 0 0
     Profit on sale of Fixed Assets 0 0 0 0 0
     Foreign Exchange Gains 2.91 2.44 0 0 0.46
     Income earned from subsidiaries/joint venture 0 0 0 0 0
     Rent / Lease Income
     Provisions Written Back 0 0 0 0 0
     Miscellaneous income -18203.64 -14268.42 -3599.84 -2964.78 -3518.49
Total Income 73.19 74.85 65.89 81.37 62.32
II. EXPENDITURE
Interest Expended 2.56 2.24 1.91 1.53 0.36
     Intereston Deposits 0 0 0 0 0
     Interest on RBI / inter-bank borrowings 0 0 0 0 0
     Other Interest 0.29 0.21 0.69 0.12 0.07
Operating Expenses 0 0 0 0 0
     Payments to and provisions for employees 10.72 9.7 8.96 9.14 7.66
     Rent,Taxes and lighting 0.2 0.44 0.46 0.42 0.45
     Depreciation on Banks property 1.39 1.06 0.96 1.05 1
     Depreciation on leased assets
     Auditor's fees and expenses 0.04 0.02 0.02 0.02 0.01
     Law charges 1.35 1.05 0.82 0.96 1.1
     Communication Expenses 0.03 0.03 0.04 0.05 0.05
     Repairs and Maintenance 0 0 0 0 0
     Insurance 0.12 0.1 0.05 0.08 0.07
     Other expenses -13.84 -12.42 -11.31 -11.73 -10.34
Provisions and Contingencies
     Provision for investments
     Provision for advances
     Others Provisions
Profit Before Tax 70.63 72.61 63.98 79.85 61.96
Taxes
     Current Income Tax 2.69 4.49 2.71 6.04 3.75
     Deferred Tax -0.89 -0.5 -0.66 -1.92 -1.12
     Other taxes 0 0 0 0 0
Profit After Tax 13.55 16.22 10.14 21.41 14.84
Extra items
Minority Interest
Share of Associate
Other Consolidated Items
Consolidated Net Profit 13.55 16.22 10.14 21.41 14.84
Adjustments to PAT
IV. APPROPRIATIONS
     Transfer to Statutory Reserve
     Appropriation to General Reserve
     Appropriation to Revenue Reserve
     Appropriation to Other Reserves 0.73 0.72 0.69 0.7 -0.26
     Equity Dividend 0.56
     Corporate dividend tax 0.11
     Other appropriations 113.4 100.59 85.09 75.63 54.93
Equity Dividend % 250 200 200 200 200
Earnings Per Share 48.00 57.49 35.95 75.86 52.60
Adjusted EPS 48.00 57.49 35.95 75.86 52.60

Financial Ratios

Particulars Mar-2020 Mar-2019 Mar-2018 Mar-2017 Mar-2016
Operational & Financial Ratios
Earnings Per Share (Rs) 27.5 32.78 28.49 39.3 26.34
DPS(Rs) 2.5 2 2 2 2
Book NAV/Share(Rs) 214.65 198.27 182.62 159.16 128.59
Margin Ratios
Yield on Advances 0 0 0 0 0
Yield on Investments 0 0 0 0 0
Cost of Liabilities 0 0 0 0 0
NIM 0 0 0 0 0
Interest Spread 0 0 0 0 0
Performance Ratios
ROA(%) 6.17 7.98 7.4 11.33 8.52
ROE(%) 13.32 17.21 16.67 27.31 27.46
ROCE(%) 14.04 16.47 14.77 20.54 18.53
Efficiency Ratios
Cost Income Ratio 0 0 0 0 0
Core Cost Income Ratio 0 0 0 0 0
Operating Costs to Assets 0 0 0 0 0
Capital Adequacy
Basel I
Total CAR (Basel I) 0 0 0 0 0
Tier-1 (Basel I) 0 0 0 0 0
Tier-2 (Basel I) 0 0 0 0 0
Basel II
Total CAR (Basel II) 0 0 0 0 0
Tier-1 (Basel II) 0 0 0 0 0
Tier-2 (Basel II) 0 0 0 0 0
Basel III
Total CAR (Basel III) 0 0 0 0 0
Tier - 1 (Basel III) 0 0 0 0 0
Tier - 2 (Basel III) 0 0 0 0 0
Valuation Parameters
PER(x) 7.49 19.69 18.51 21.83 30.15
PCE(x) 4.87 14.56 13.45 17.63 22.93
Price/Book(x) 0.96 3.26 2.89 5.39 6.18
Yield(%) 1.21 0.31 0.38 0.23 0.25
EV/Net Sales(x) 0.9 2.2 2.01 3.07 3.38
EV/Core EBITDA(x) 5.15 12.11 10.71 13.44 17.53
EV/EBIT(x) 6.5 13.29 13.01 16.12 20.89
EV/CE(x) 0.72 1.82 1.62 2.67 2.8
M Cap / Sales 0.55 1.85 1.64 2.67 2.96
Growth Ratio
Core Operating Income Growth 12.77 17.17 20.33 32.67 -5.92
Operating Profit Growth 3.55 5.11 -17.71 42.34 19.32
Net Profit Growth -16.11 15.07 -27.5 49.22 254.72
BVPS Growth 8.26 8.57 14.74 23.78 95.59
Advances Growth 0 0 0 0 0
EPS Growth(%) -16.11 15.08 -27.51 49.18 241.03
Liquidity Ratios
Loans/Deposits(x) 0 0 0 0 0
Total Debt/Equity(x) 0 0 0 0 0
Current Ratio(x) 0 0 0 0 0
Quick Ratio(x) 0 0 0 0 0
Interest Cover(x)
Total Debt/Mcap(x) 0 0 0 0 0
Net NPA in Rs. Million 0 0 0 0 0
Particulars Mar-2020 Mar-2019 Mar-2018 Mar-2017 Mar-2016
Operational & Financial Ratios
Earnings Per Share (Rs) 48 57.49 35.95 75.86 52.6
DPS(Rs) 2.5 2 2 2 2
Book NAV/Share(Rs) 100 100 100 100 100
Margin Ratios
Yield on Advances 0 0 0 0 0
Yield on Investments 0 0 0 0 0
Cost of Liabilities 0 0 0 0 0
NIM 0 0 0 0 0
Interest Spread 0 0 0 0 0
Performance Ratios
ROA(%) 7.83 10.45 6.78 16.27 15.2
ROE(%) 10.77 14.54 10.24 25.48 24.1
ROCE(%) 11.24 15.78 11.02 26.57 26.38
Efficiency Ratios
Cost Income Ratio 0 0 0 0 0
Core Cost Income Ratio 0 0 0 0 0
Operating Costs to Assets 0 0 0 0 0
Capital Adequacy
Basel I
Total CAR (Basel I) 0 0 0 0 0
Tier-1 (Basel I) 0 0 0 0 0
Tier-2 (Basel I) 0 0 0 0 0
Basel II
Total CAR (Basel II) 0 0 0 0 0
Tier-1 (Basel II) 0 0 0 0 0
Tier-2 (Basel II) 0 0 0 0 0
Basel III
Total CAR (Basel III) 0 0 0 0 0
Tier - 1 (Basel III) 0 0 0 0 0
Tier - 2 (Basel III) 0 0 0 0 0
Valuation Parameters
PER(x) 4.29 11.23 14.66 11.31 15.1
PCE(x) 3.89 10.54 13.4 10.78 14.15
Price/Book(x) 0.44 1.53 1.43 2.57 3.04
Yield(%) 1.21 0.31 0.38 0.23 0.25
EV/Net Sales(x) 1.39 3.01 2.76 3.35 3.78
EV/Core EBITDA(x) 4.87 10.52 11.74 8.77 12.28
EV/EBIT(x) 5.19 9.4 12.54 9.88 12.97
EV/CE(x) 0.51 1.28 1.21 1.74 2.11
M Cap / Sales 0.87 2.6 2.32 3.03 3.66
Growth Ratio
Core Operating Income Growth 14.55 17.24 25.1 100 19.99
Operating Profit Growth -4.73 33.23 -50.58 61.85 21.46
Net Profit Growth -16.49 59.92 -52.61 44.22 47.32
BVPS Growth 10.74 14.94 10.02 28.11 42.99
Advances Growth 0 0 0 0 0
EPS Growth(%) -16.49 59.92 -52.61 44.21 41.64
Liquidity Ratios
Loans/Deposits(x) 0 0 0 0 0
Total Debt/Equity(x) 0 0 0 0 0
Current Ratio(x) 0 0 0 0 0
Quick Ratio(x) 0 0 0 0 0
Interest Cover(x)
Total Debt/Mcap(x) 0 0 0 0 0
Net NPA in Rs. Million 0 0 0 0 0

Cash Flow

(₹ in Million)
Particulars Mar-2020 Mar-2019 Mar-2018 Mar-2017 Mar-2016
Net Profit Before Taxes 10.96 13.01 11.19 14.91 10.44
Adjustments for Expenses & Provisions : 6.36 3.3 5.71 7.27 3.91
Adjustments for Liabilities & Assets: 1.27 1.36 3.09 -8.62 -6.12
Refund/(payment) of direct taxes -4.67 -4.43 -3.52 -6.99 -4.78
Other Direct payments 0 0 0 0 0
Cash Flow from operating activities 13.92 13.24 16.48 6.57 3.45
Cash Flow from investing activities -7.84 -6.99 -10.13 -7.12 -8.8
Cash Flow from financing activities -4.45 -7.39 -4.68 5.43 6.99
Effect of exchange fluctuation on translation reserve 0 0 0 0 0
Net increase/(decrease) in cash and cash equivalents 1.64 -1.14 1.66 4.88 1.63
Opening Cash & Cash Equivalents 9.36 12.33 10.56 8.57 7.64
Cash & Cash Equivalent on Amalgamation / Take over / Merger 0 0 0 0 0
Cash & Cash Equivalent of Subsidiaries under liquidations 0 0 0 0 0
Translation adjustment on reserves / op cash balalces frgn subsidiaries 0 0 0 0 0
Effect of Foreign Exchange Fluctuations 0.1 -1.84 0.11 -2.89 -0.7
Closing Cash & Cash Equivalent 11.1 9.36 12.33 10.56 8.57
Cash & Cash Equivalent on Amalgamation / Take over / Merger 0 0 0 0 0
Cash & Cash Equivalent of Subsidiaries under liquidations 0 0 0 0 0
Translation adjustment on reserves / op cash balalces frgn subsidiaries 0 0 0 0 0
Effect of Foreign Exchange Fluctuations 0.1 -1.84 0.11 -2.89 -0.7
(₹ in Million)
Particulars Mar-2020 Mar-2019 Mar-2018 Mar-2017 Mar-2016
Net Profit Before Taxes 10.96 13.01 11.19 14.91 10.44
Adjustments for Expenses & Provisions : 6.36 3.3 5.71 7.27 3.91
Adjustments for Liabilities & Assets: 1.27 1.36 3.09 -8.62 -6.12
Refund/(payment) of direct taxes -4.67 -4.43 -3.52 -6.99 -4.78
Other Direct payments 0 0 0 0 0
Cash Flow from operating activities 13.92 13.24 16.48 6.57 3.45
Cash Flow from investing activities -7.84 -6.99 -10.13 -7.12 -8.8
Cash Flow from financing activities -4.45 -7.39 -4.68 5.43 6.99
Effect of exchange fluctuation on translation reserve 0 0 0 0 0
Net increase/(decrease) in cash and cash equivalents 1.64 -1.14 1.66 4.88 1.63
Opening Cash & Cash Equivalents 9.36 12.33 10.56 8.57 7.64
Cash & Cash Equivalent on Amalgamation / Take over / Merger 0 0 0 0 0
Cash & Cash Equivalent of Subsidiaries under liquidations 0 0 0 0 0
Translation adjustment on reserves / op cash balalces frgn subsidiaries 0 0 0 0 0
Effect of Foreign Exchange Fluctuations 0.1 -1.84 0.11 -2.89 -0.7
Closing Cash & Cash Equivalent 11.1 9.36 12.33 10.56 8.57
Cash & Cash Equivalent on Amalgamation / Take over / Merger 0 0 0 0 0
Cash & Cash Equivalent of Subsidiaries under liquidations 0 0 0 0 0
Translation adjustment on reserves / op cash balalces frgn subsidiaries 0 0 0 0 0
Effect of Foreign Exchange Fluctuations 0.1 -1.84 0.11 -2.89 -0.7

Share Price

Year Open Price (₹) High Price (₹) Low Price (₹) Close Price (₹) Volume (000's) Value (in Lakhs)
February-2021 475 513.2 464.1 504.2 997.46 4970.4
January-2021 495 531.95 469.75 472.35 2513.38 12719.64
December-2020 475 548 464.45 498.75 2959.5 15205.81
November-2020 469 515.5 460.45 471.2 2560.73 12392.25
October-2020 488 509.1 464.75 475.2 2304.61 11255.7
September-2020 469.75 518.1 441.65 482.4 3279.02 15786.82
August-2020 455.5 508.5 442.45 469.4 6540.61 31068.56
Glenmark Pharmaceuticals informs about media release03-May-2021 09:41 AM  
Glenmark launches Ryaltris-AZ at affordable price in India 03-May-2021 09:27 AM  
Glenmark Pharma to launch nasal spray Ryaltris in EU26-Apr-2021 01:16 PM  
Glenmark Pharm surges as its arm files draft red herring prospectus with SEBI for IPO19-Apr-2021 12:58 PM  
Glenmark Pharmaceuticals’ arm files draft red herring prospectus with SEBI for IPO17-Apr-2021 12:18 PM  
Glenmark Pharmaceuticals informs about proposed IPO of wholly owned subsidiary17-Apr-2021 12:05 PM  
Glenmark Pharmaceuticals informs about media release24-Mar-2021 10:52 AM  
Glenmark Pharma trades in green on getting USFDA’s nod for Chlorpromazine Hydrochloride Tablets 24-Mar-2021 09:55 AM  
Glenmark Pharma gets USFDA’s nod for Chlorpromazine Hydrochloride Tablets24-Mar-2021 09:36 AM  
Glenmark Pharmaceuticals gets $40 million COVID credit line from IFC23-Mar-2021 03:18 PM  
Glenmark Pharmaceuticals informs about media release23-Mar-2021 10:45 AM  
Glenmark moves up on getting USFDA’s nod for Diltiazem Hydrochloride Extended-Release Capsules23-Mar-2021 10:12 AM  
Glenmark Pharma gets USFDA’s approval for Diltiazem Hydrochloride Extended-Release Capsules23-Mar-2021 09:59 AM  
Glenmark Pharma gains as its arm inks pact with Bausch Health to commercialize RYALTRIS nasal spray in Canada22-Mar-2021 10:40 AM  
Glenmark Pharma’s arm inks pact with Bausch Health to commercialize RYALTRIS nasal spray in Canada22-Mar-2021 10:25 AM  
Glenmark signs Rohit Sharma as brand ambassador of Candid Powder 05-Mar-2021 09:45 AM  
Glenmark Pharma wins ‘India Pharma Innovation of the Year’ Award 25-Feb-2021 02:38 PM  
Glenmark Pharmaceuticals informs about media release22-Feb-2021 10:13 AM  
Glenmark Pharmaceuticals’ arm receives approval for Ryaltris Nasal Spray22-Feb-2021 08:59 AM  
Glenmark Pharmaceuticals informs about media release16-Feb-2021 10:24 AM  
Glenmark Pharmaceuticals launches SUTIB to treat kidney cancer in India16-Feb-2021 09:33 AM  
Glenmark Pharma reports 30% rise in Q3 consolidated net profit13-Feb-2021 09:59 AM  
Glenmark Pharmaceuticals gets final approval for Clindamycin Phosphate Gel from USFDA11-Feb-2021 11:37 AM  
Glenmark Pharmaceuticals informs about media release11-Feb-2021 10:58 AM  
Glenmark Pharmaceuticals informs about media release03-Feb-2021 10:30 AM  
Glenmark soars on getting USFDA’s nod for Topiramate Extended-Release Capsules03-Feb-2021 10:20 AM  
Glenmark gets USFDA’s nod for Topiramate Extended-Release Capsules03-Feb-2021 09:58 AM  
Glenmark Pharmaceuticals informs about media release28-Jan-2021 10:22 AM  
Glenmark gets USFDA’s nod for Amphetamine Sulfate Tablets28-Jan-2021 09:52 AM  
Glenmark gains on getting tentative nod for Gabapentin Enacarbil Extended-Release Tablets, Apremilast Tablets31-Dec-2020 10:35 AM  
Glenmark gets tentative nod for Gabapentin Enacarbil Extended-Release Tablets, Apremilast Tablets31-Dec-2020 09:50 AM  
Glenmark Pharmaceuticals gets USFDA’s final nod for Tadalafil Tablets31-Dec-2020 09:50 AM  
Glenmark inches up on launching Remogliflozin + Vildagliptin fixed dose combination29-Dec-2020 03:18 PM  
Glenmark becomes first company to launch Remogliflozin + Vildagliptin fixed dose combination29-Dec-2020 01:12 PM  
Glenmark Pharmaceuticals informs about media release23-Dec-2020 10:36 AM  
Glenmark Pharmaceuticals shines as its arm enters into licensing agreement with Menarini Group23-Dec-2020 10:08 AM  
Glenmark Pharmaceuticals’ arm enters into licensing agreement with Menarini Group23-Dec-2020 09:36 AM  
Glenmark Pharmaceuticals moves up on getting tentative approval for Dabigatran Etexilate Capsules21-Dec-2020 10:53 AM  
Glenmark Pharmaceuticals gets tentative approval for Dabigatran Etexilate Capsules21-Dec-2020 10:40 AM  
Glenmark Pharmaceuticals informs about media release21-Dec-2020 10:30 AM  
Glenmark Pharmaceuticals informs about disclosure01-Dec-2020 05:20 PM  
Glenmark Pharmaceuticals soars as its arm gets tentative approval for Axitinib Tablets01-Dec-2020 10:53 AM  
Glenmark Pharmaceuticals’ arm gets tentative approval for Axitinib Tablets01-Dec-2020 10:46 AM  
Glenmark Pharmaceuticals informs about media release01-Dec-2020 10:40 AM  
Glenmark to divest select brands to Dr Reddy’s in Russia, Ukraine, Kazakhstan and Uzbekistan30-Nov-2020 09:16 AM  
Glenmark Pharma gains on the bourses26-Nov-2020 01:57 PM  
Glenmark secures position in Dow Jones Sustainability Emerging Markets Index 26-Nov-2020 12:58 PM  
Glenmark Pharmaceuticals informs about media release23-Nov-2020 01:48 PM